Compare · JNJ vs ZIVO
JNJ vs ZIVO
Side-by-side comparison of Johnson & Johnson (JNJ) and Zivo Bioscience Inc. (ZIVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and ZIVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $613.10B, about 25033.7x ZIVO ($24.5M).
- JNJ has hit the wire 20 times in the past 4 weeks while ZIVO has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 1 for ZIVO).
- Company
- Johnson & Johnson
- Zivo Bioscience Inc.
- Price
- -
- -
- Market cap
- $613.10B
- $24.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 20
- 0
- Recent ratings
- 25
- 1
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Zivo Bioscience Inc.
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Keego Harbor, Michigan.
Latest JNJ
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
- Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
- Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
- SEC Form 10-Q filed by Johnson & Johnson
Latest ZIVO
- Large owner Strome Mark E bought $200,000 worth of shares (100,000 units at $2.00) (SEC Form 4)
- ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass
- SEC Form EFFECT filed by Zivo Bioscience Inc.
- Zivo Bioscience Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- ZIVO Bioscience Provides Special Letter to Shareholders
- Director Yaldoo Laith L bought $14,998 worth of shares (1,543 units at $9.72) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Zivo Bioscience Inc.
- Large owner Strome Mark E bought $195,400 worth of shares (20,000 units at $9.77) (SEC Form 4)
- Director Yaldoo Laith L bought $24,997 worth of shares (2,434 units at $10.27) (SEC Form 4)
- Director Cornell Alison A bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 4% to 279,481 units (SEC Form 4)